Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids

Antonio Luchicchi, Marco Pistis

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Since the discovery of endocannabinoids and their receptors, two major members of the endocannabinoid family, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been regarded almost as twin brothers. Pharmacological properties were initially considered to be similar, as these molecules were believed mutually exchangeable and almost indistinguishable in the regulation of synaptic functions, such as long- and short-term synaptic plasticity, and in behavioral aspects, such as learning and memory, reward and addiction, antinociception, and anxiety. In recent years, however, endocannabinoid signaling specificity began to emerge, in particular, due to the production of genetically engineered mice lacking key enzymes in endocannabinoid synthesis or degradation, together with the development of selective inhibitors of AEA or 2-AG catabolic enzymes. Evidence now suggests that AEA and 2-AG possess specific pharmacological properties, are engaged in different forms of synaptic plasticity, and take part in different behavioral functions. In this review, we provide an overview on similarities and specificities of the two endocannabinoids in the CNS and on the unresolved questions concerning their role in synaptic signaling.

Original languageEnglish
Pages (from-to)374-92
Number of pages19
JournalMolecular Neurobiology
Volume46
Issue number2
DOIs
Publication statusPublished - Oct 2012
Externally publishedYes

Cite this

@article{1200606eaac14b75ab45f5c936a03692,
title = "Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids",
abstract = "Since the discovery of endocannabinoids and their receptors, two major members of the endocannabinoid family, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been regarded almost as twin brothers. Pharmacological properties were initially considered to be similar, as these molecules were believed mutually exchangeable and almost indistinguishable in the regulation of synaptic functions, such as long- and short-term synaptic plasticity, and in behavioral aspects, such as learning and memory, reward and addiction, antinociception, and anxiety. In recent years, however, endocannabinoid signaling specificity began to emerge, in particular, due to the production of genetically engineered mice lacking key enzymes in endocannabinoid synthesis or degradation, together with the development of selective inhibitors of AEA or 2-AG catabolic enzymes. Evidence now suggests that AEA and 2-AG possess specific pharmacological properties, are engaged in different forms of synaptic plasticity, and take part in different behavioral functions. In this review, we provide an overview on similarities and specificities of the two endocannabinoids in the CNS and on the unresolved questions concerning their role in synaptic signaling.",
keywords = "Animals, Arachidonic Acids, Endocannabinoids, Glycerides, Humans, Memory, Neuronal Plasticity, Neuroprotective Agents, Nociception, Polyunsaturated Alkamides, Journal Article, Research Support, Non-U.S. Gov't, Review",
author = "Antonio Luchicchi and Marco Pistis",
year = "2012",
month = "10",
doi = "10.1007/s12035-012-8299-0",
language = "English",
volume = "46",
pages = "374--92",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press",
number = "2",

}

Anandamide and 2-arachidonoylglycerol : pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids. / Luchicchi, Antonio; Pistis, Marco.

In: Molecular Neurobiology, Vol. 46, No. 2, 10.2012, p. 374-92.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Anandamide and 2-arachidonoylglycerol

T2 - pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids

AU - Luchicchi, Antonio

AU - Pistis, Marco

PY - 2012/10

Y1 - 2012/10

N2 - Since the discovery of endocannabinoids and their receptors, two major members of the endocannabinoid family, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been regarded almost as twin brothers. Pharmacological properties were initially considered to be similar, as these molecules were believed mutually exchangeable and almost indistinguishable in the regulation of synaptic functions, such as long- and short-term synaptic plasticity, and in behavioral aspects, such as learning and memory, reward and addiction, antinociception, and anxiety. In recent years, however, endocannabinoid signaling specificity began to emerge, in particular, due to the production of genetically engineered mice lacking key enzymes in endocannabinoid synthesis or degradation, together with the development of selective inhibitors of AEA or 2-AG catabolic enzymes. Evidence now suggests that AEA and 2-AG possess specific pharmacological properties, are engaged in different forms of synaptic plasticity, and take part in different behavioral functions. In this review, we provide an overview on similarities and specificities of the two endocannabinoids in the CNS and on the unresolved questions concerning their role in synaptic signaling.

AB - Since the discovery of endocannabinoids and their receptors, two major members of the endocannabinoid family, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), have been regarded almost as twin brothers. Pharmacological properties were initially considered to be similar, as these molecules were believed mutually exchangeable and almost indistinguishable in the regulation of synaptic functions, such as long- and short-term synaptic plasticity, and in behavioral aspects, such as learning and memory, reward and addiction, antinociception, and anxiety. In recent years, however, endocannabinoid signaling specificity began to emerge, in particular, due to the production of genetically engineered mice lacking key enzymes in endocannabinoid synthesis or degradation, together with the development of selective inhibitors of AEA or 2-AG catabolic enzymes. Evidence now suggests that AEA and 2-AG possess specific pharmacological properties, are engaged in different forms of synaptic plasticity, and take part in different behavioral functions. In this review, we provide an overview on similarities and specificities of the two endocannabinoids in the CNS and on the unresolved questions concerning their role in synaptic signaling.

KW - Animals

KW - Arachidonic Acids

KW - Endocannabinoids

KW - Glycerides

KW - Humans

KW - Memory

KW - Neuronal Plasticity

KW - Neuroprotective Agents

KW - Nociception

KW - Polyunsaturated Alkamides

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1007/s12035-012-8299-0

DO - 10.1007/s12035-012-8299-0

M3 - Review article

VL - 46

SP - 374

EP - 392

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 2

ER -